Progenity to Participate in Two Upcoming Investor Conferences
10 févr. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Reaches Two Million Test Milestone
20 janv. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Provides Financial Guidance for Full-year 2021
13 janv. 2021 16h05 HE
|
Progenity, Inc.
Total 2021 revenue expected to grow by up to 30%1, reaching a range of $130 to $145 million Core molecular testing2 volume expected to grow by up to 16% SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE)...
Victorian Era History, Mystery and Death Puts Readers at the Edge of Their Seats in New Suspense Novel
11 janv. 2021 09h12 HE
|
XlibrisAU
SYDNEY, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Author of the medieval trilogy books, “A Wicked Winter,” “The Secret Face” and “The Chalcedony Axe,” Richard Watkins introduces a new gothic mystery novel...
Progenity to Present at the 2021 ICR Conference
05 janv. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Expands Availability of COVID-19 PCR Testing Services Across United States
17 déc. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Closing of the Convertible Senior Notes Offering and Partial Exercise of the Initial Purchaser’s Option to Purchase Additional Notes
08 déc. 2020 07h31 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Closing of Public Offering of Common Stock
08 déc. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
Progenity, Inc. Prices $75.0 Million Convertible Senior Notes Offering
02 déc. 2020 23h51 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million aggregate principal amount of 7.25% convertible senior notes...
Progenity Announces Pricing of Public Offering of Common Stock
02 déc. 2020 23h50 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...